相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical efficacy of bortezomib and lenalidomide in blastic plasmacytoid dendritic cell neoplasm
Chunli Yang et al.
ANNALS OF HEMATOLOGY (2019)
Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report
Katrine F. Iversen et al.
HAEMATOLOGICA (2019)
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Naveen Pemmaraju et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
Justin Taylor et al.
BLOOD (2019)
The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm
Vincent Marmouset et al.
HEMATOLOGICAL ONCOLOGY (2019)
Allogeneic CAR T cell therapies for leukemia
Waseem Qasim
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies
Naval G. Daver et al.
BLOOD (2018)
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
Joan Montero et al.
CANCER DISCOVERY (2017)
Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm
Laure Philippe et al.
HAEMATOLOGICA (2017)
Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors
Alexandra-Chloe Villani et al.
SCIENCE (2017)
Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm
Laure Philippe et al.
HAEMATOLOGICA (2017)
Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study
Mohamed A. Kharfan-Dabaja et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm
Matthew L. Ulrickson et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms
Anouk Emadali et al.
BLOOD (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
A Druggable TCF4-and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm
Michele Ceribelli et al.
CANCER CELL (2016)
Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases
Raida Khwaja et al.
LEUKEMIA & LYMPHOMA (2016)
IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models
Sharlene Adams et al.
BLOOD (2016)
Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Tianyu Cai et al.
BLOOD (2016)
Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm
Tomohiro Aoki et al.
BLOOD (2015)
Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile
Lourdes Martin-Martin et al.
ONCOTARGET (2015)
Expanding role of lenalidomide in hematologic malignancies
Nilanjan Ghosh et al.
CANCER MANAGEMENT AND RESEARCH (2015)
Blastic Plasmacytoid Dendritic Cell Neoplasm: Skin and Bone Marrow Infiltration of Three Cases and the Review of the Literature
Figen Atalay et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2015)
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
Arthur E. Frankel et al.
BLOOD (2014)
Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-Azacytidine
Kamel Laribi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition
M. R. Sapienza et al.
LEUKEMIA (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Blastic Plasmacytoid Dendritic Cell Neoplasm: Update on Molecular Biology, Diagnosis, and Therapy
Wasif Riaz et al.
CANCER CONTROL (2014)
CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
Ugo Testa et al.
BIOMARKER RESEARCH (2014)
Blastic plasmacytoid dendritic cell neoplasm with extensive cutaneous and central nervous system involvement
Hayder Saeed et al.
RARE TUMORS (2014)
Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus on Hematopoietic Cell Transplantation
Mohamed A. Kharfan-Dabaja et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation
Damien Roos-Weil et al.
BLOOD (2013)
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study
Livio Pagano et al.
HAEMATOLOGICA (2013)
Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm
Naveen Pemmaraju et al.
BLOOD (2012)
Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion
Marco Lucioni et al.
BLOOD (2011)
Therapeutic Effect of Lenalidomide in a Novel Xenograft Mouse Model of Human Blastic NK Cell Lymphoma/Blastic Plasmacytoid Dendritic Cell Neoplasm
Alice Agliano et al.
CLINICAL CANCER RESEARCH (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?
S. Dalle et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications
Armin G. Jegalian et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: Results from the Hellenic Dendritic Cell Leukemia Study Group
Nikolaos J. Tsagarakis et al.
LEUKEMIA RESEARCH (2010)
Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia
Francine Garnache-Ottou et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia
Miroslav Djokic et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia
Arthur Frankel et al.
LEUKEMIA & LYMPHOMA (2008)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor) - Prognostication and categorization according to anatomic sites of involvement
R Suzuki et al.
CANCER (2005)
What is CD4+CD56+malignancy and how should it be treated?
P Reimer et al.
BONE MARROW TRANSPLANTATION (2003)
Clinical and biologic features of CD4(+)CD56(+) malignancies
J Feuillard et al.
BLOOD (2002)
Identification of a leukemic counterpart of the plasmacytoid dendritic cells
L Chaperot et al.
BLOOD (2001)
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells
CT Jordan et al.
LEUKEMIA (2000)
Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor
AE Frankel et al.
PROTEIN ENGINEERING (2000)
Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias
AE Frankel et al.
LEUKEMIA (2000)
分享论文
